Deng Xiaoyi, Gujjar Ramesh, El Mazouni Farah, Kaminsky Werner, Malmquist Nicholas A, Goldsmith Elizabeth J, Rathod Pradipsinh K, Phillips Margaret A
Department of Pharmacology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9041, USA.
J Biol Chem. 2009 Sep 25;284(39):26999-7009. doi: 10.1074/jbc.M109.028589. Epub 2009 Jul 28.
Malaria remains a major global health burden and current drug therapies are compromised by resistance. Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) was validated as a new drug target through the identification of potent and selective triazolopyrimidine-based DHODH inhibitors with anti-malarial activity in vivo. Here we report x-ray structure determination of PfDHODH bound to three inhibitors from this series, representing the first of the enzyme bound to malaria specific inhibitors. We demonstrate that conformational flexibility results in an unexpected binding mode identifying a new hydrophobic pocket on the enzyme. Importantly this plasticity allows PfDHODH to bind inhibitors from different chemical classes and to accommodate inhibitor modifications during lead optimization, increasing the value of PfDHODH as a drug target. A second discovery, based on small molecule crystallography, is that the triazolopyrimidines populate a resonance form that promotes charge separation. These intrinsic dipoles allow formation of energetically favorable H-bond interactions with the enzyme. The importance of delocalization to binding affinity was supported by site-directed mutagenesis and the demonstration that triazolopyrimidine analogs that lack this intrinsic dipole are inactive. Finally, the PfDHODH-triazolopyrimidine bound structures provide considerable new insight into species-selective inhibitor binding in this enzyme family. Together, these studies will directly impact efforts to exploit PfDHODH for the development of anti-malarial chemotherapy.
疟疾仍然是全球主要的健康负担,当前的药物治疗因耐药性而受到影响。恶性疟原虫二氢乳清酸脱氢酶(PfDHODH)通过鉴定在体内具有抗疟活性的强效且选择性的基于三唑并嘧啶的DHODH抑制剂,被确认为一个新的药物靶点。在此,我们报告了PfDHODH与该系列中的三种抑制剂结合的X射线晶体结构测定,这是该酶与疟疾特异性抑制剂结合的首个结构。我们证明构象灵活性导致了一种意想不到的结合模式,在该酶上确定了一个新的疏水口袋。重要的是,这种可塑性使PfDHODH能够结合来自不同化学类别的抑制剂,并在先导优化过程中容纳抑制剂修饰,从而增加了PfDHODH作为药物靶点的价值。基于小分子晶体学的第二个发现是,三唑并嘧啶呈现出一种促进电荷分离的共振形式。这些内在偶极允许与该酶形成能量上有利的氢键相互作用。定点诱变以及缺乏这种内在偶极的三唑并嘧啶类似物无活性的证明支持了离域对结合亲和力的重要性。最后,PfDHODH-三唑并嘧啶结合结构为该酶家族中物种选择性抑制剂的结合提供了相当多的新见解。总之,这些研究将直接影响利用PfDHODH开发抗疟化疗药物的努力。